Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment.
Quantitative isotropic diffusion MRI and voxel-based analysis of the apparent diffusion coefficient (ADC) changes have been demonstrated to be able to accurately predict early response of brain tumors to therapy. The ADC value changes measured during pre- and posttherapy interval are closely correlated to treatment response. This work was demonstrated using a voxel-based analysis of ADC change during therapy in the brains of both rats and humans, following rigidly registering pre- and post-therapeutic ADC MRI exams. The primary goal of this paper is to extend this voxel-by-voxel analysis to assess therapeutic response in breast cancer. Nonlinear registration (with higher degrees of freedom) between the pre- and post-treatment exams is needed to ensure that the corresponding voxels actually contain similar cellular partial contributions due to soft tissue deformations in the breast and compartmental tumor changes during treatment as well. With limited data sets, we have observed the correlation between changes of ADC values and treatment response also exists in breast cancers. With diffusion scans acquired at three different timepoints (pre-treatment, early post-treatment and late post-treatment), we have also shown that ADC changes across responders within 5 weeks are a function of time interval after the initiation of treatment. Comparison of the experimental results with pathology shows that ADC changes can be used to evaluate early response of breast cancer treatment.
Ma
Bing
B
Department of Radiology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA. bingm@umich.edu
Meyer
Charles R
CR
Pickles
Martin D
MD
Chenevert
Thomas L
TL
Bland
Peyton H
PH
Galbán
Craig J
CJ
Rehemtulla
Alnawaz
A
Turnbull
Lindsay W
LW
Ross
Brian D
BD
D000465:Algorithms; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001185:Artificial Intelligence; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D005260:Female; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007090:Image Interpretation, Computer-Assisted / Q000379:methods*; D021621:Imaging, Three-Dimensional / Q000379:methods*; D010363:Pattern Recognition, Automated / Q000379:methods*; D011379:Prognosis; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome
D000970:Antineoplastic Agents
J Clin Oncol. 2008 Jul 10;26(20):3387-94
18541899
Cancer J. 2001 Sep-Oct;7(5):413-20
11693900
J Clin Oncol. 1999 Feb;17(2):460-9
10080586
Cancer Res. 2006 May 1;66(9):4687-92
16651420
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):443-50
17255264
J Clin Oncol. 1998 Aug;16(8):2672-85
9704717
Mol Cancer Ther. 2003 Jun;2(6):581-7
12813138
J Clin Oncol. 1998 Jan;16(1):93-100
9440728
Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9
15805192
Q Magn Reson Biol Med. 1994;1(2):89-106
26550608
Breast Cancer Res Treat. 2005 Aug;92(3):231-8
16155794
Mol Imaging. 2002 Oct;1(4):336-43
12926229
Magn Reson Imaging. 2006 Sep;24(7):843-7
16916701
Med Image Anal. 1997 Apr;1(3):195-206
9873906
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64
16267128
J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36
11121466
Cancer Res. 2007 Apr 15;67(8):3524-8
17440058
Neoplasia. 2007 Dec;9(12):1003-11
18084607